FDA Inspection 1122373 — Apex Biologics

Apex Biologics — FEI 3010131579

The FDA completed an inspection of Apex Biologics on March 12, 2020 in Alpine, UT. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
March 12, 2020
Fiscal Year
2020
Product Type
Biologics
Project Area
Human Cellular, Tissue, and Gene Therapies
Location
Alpine, UT (United States)